Ovid Therapeutics And Graviton Bioscience Announces Topline Data From Phase 1 Clinical Trial Studying OV888/GV101 Capsule For Cerebral Cavernous Malformations

7/1/24 8:03:48 AM ET

$OVID

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $OVID alert in real time by email

The Phase 1 study for OV888/GV101 capsule met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse events
Secondary endpoint results indicate that the target pharmacokinetic profile was achieved at the targeted clinical dose, supporting once daily dosing
OV888/GV101 capsule was shown to be biologically active in participants and elicited dose-dependent pharmacodynamic effects within the planned therapeutic dose range
- A Phase 2 study for the treatment of cerebral cavernous malformations is expected to initiate in the second half of 2024

Get the next $OVID alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$OVID

Date	Price Target	Rating	Analyst
6/18/2024		Outperform → Perform	Oppenheimer
4/30/2024	$9.00	Buy	B. Riley Securities
4/29/2024	$9.00	Buy	H.C. Wainwright
4/5/2024	$8.00	Outperform	Wedbush
12/21/2023	$11.00	Buy	BTIG Research
10/13/2023	$8.00	Outperform	Oppenheimer
8/25/2021	$4.50 → $4.00	Neutral	Citigroup

More analyst ratings

$OVID
Press Releases

Fastest customizable press release news feed in the world

Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results
A Phase 1 SAD/MAD study of OV329 is progressing as planned, and based on encouraging human safety data to date, Ovid will engage regulators about adding cohorts to increase potential dosing opportunities for Phase 2 programs.A regulatory application for a Phase 1 trial of OV350, the first candidate from Ovid's KCC2 direct activator library, is expected to be filed in Q4 2024.The Company will host a KCC2 Download Day on November 13 to provide updates on Ovid's platform of KCC2 direct activators and their broad therapeutic potential.Ovid and Graviton are pausing the initiation of a Phase 2 study of OV888/GV101 to evaluate emerging insights from two recently completed competitor trials in cereb
11/12/24 8:00:00 AM ET
$OVID
Biotechnology: Pharmaceutical Preparations
Health Care
Ovid Therapeutics to Host Investor Event
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced that it will host an investor event focused on its portfolio of direct potassium chloride co-transporter 2 (KCC2) activators on Wednesday, November 13, 2024. The event will take place at Ovid's headquarters in New York's Hudson Yards from 9:30 to 11:30 am ET and will be webcast simultaneously. The session will focus on the biological relevance and broad potential therapeutic opportunity associated with Ovid's KCC2 portfolio. Company management will provide updates on the po
10/31/24 8:00:00 AM ET
$OVID
Biotechnology: Pharmaceutical Preparations
Health Care
Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin
Study found OV329 cleared and remained undetectable in the retina, eye, and brain tissues of mice, unlike vigabatrin which has repeatedly shown to preferentially accumulate in mouse retinas, eyes, and other tissues OV329's potency, mechanism of inhibition, short half-life, rapid tissue elimination and prolonged pharmacodynamic effect suggests it delivers a differentiated ocular safety and efficacy profile from vigabatrin A Phase 1 trial evaluating OV329 in healthy volunteers is on-track for completion in late 2024 and will evaluate safety and two biomarkers for target engagement and evidence of clinical effect NEW YORK, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:O
9/26/24 8:00:00 AM ET
$OVID
Biotechnology: Pharmaceutical Preparations
Health Care

$OVID
Leadership Updates

Live Leadership Updates

Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer
NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced the appointment of Amanda Banks, M.D., as Chief Development Officer. Dr. Banks will oversee Ovid's clinical development, medical, and regulatory affairs functions as well as drive corporate development strategy and execution in partnership with the Company's leadership team. Dr. Banks brings to Ovid broad and deep experience in neurology, clinical strategy, and business development. Her strategic acumen will serve Ovid at an important juncture for the Company as it determ
8/8/24 8:00:00 AM ET
$OVID
Biotechnology: Pharmaceutical Preparations
Health Care
Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists
Neurologists/epileptologists Dr. Imad Najm of the Cleveland Clinic Neurological Institute and the Cleveland Clinic Epilepsy Center, and Dr. Raman Sankar, the Emeritus Chief of Pediatric Neurology at UCLA Health, appointed to Ovid's Scientific Advisory Board (SAB)Neuroscientists Dr. Jamie Maguire of Tufts University and Dr. Jeff Noebels of Baylor College of Medicine, appointed to the SAB to contribute expertise in neurophysiology, hyperexcitability and network effectsThe SAB will advise on the potential application of Ovid's compounds to broader disorders in which they may offer therapeutic promise, including brain conditions caused by hyperexcitability, neurovascular and neuro-inflammatory d
7/23/24 8:00:00 AM ET
$OVID
Biotechnology: Pharmaceutical Preparations
Health Care
Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer
Dr. Zhong Zhong joins Ovid as Chief Scientific Officer (CSO) and Dr. Manoj Malhotra assumes role as Chief Medical Officer (CMO) following the planned retirement of Dr. Claude NicaiseMeg Alexander promoted to Chief Strategy OfficerOvid streamlined G&A infrastructure to improve operational efficiency and reduce costs NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today announced leadership appointments intended to enhance the execution of its corporate strategy and the scientific stewardship of its therapeutic
6/28/23 8:00:00 AM ET
$OVID
Biotechnology: Pharmaceutical Preparations
Health Care

$OVID
Market Insights

Live Market Insights

Ovid Therapeutics Announces eNeuro Publishes Findings On The Anti-Convulsant Properties Of OV329 And Its Potential Effectiveness In Treatment-Resistant Seizures
Sustained exposure to OV329 in preclinical models reduced GABA-aminotransferase (GABA-AT) activity, increased steady state GABA levels in the brain, and induced phasic and tonic inhibition OV329 demonstrated anti-convulsant effects in mice, reducing the severity of status epilepticus and preventing the development of benzodiazepine-resistant seizures OV329 was shown to have a higher potency (as measured by IC50) for the GABA-AT target than published studies of vigabatrin, an FDA-approved GABA-AT inhibitor NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brai
7/10/24 8:02:07 AM ET
$OVID
Biotechnology: Pharmaceutical Preparations
Health Care
HC Wainwright & Co. Reiterates Buy on Ovid Therapeutics, Maintains $3 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Ovid Therapeutics (NASDAQ:OVID) with a Buy and maintains $3 price target.
7/2/24 6:23:50 AM ET
$OVID
Biotechnology: Pharmaceutical Preparations
Health Care
Ovid Therapeutics And Graviton Bioscience Announces Topline Data From Phase 1 Clinical Trial Studying OV888/GV101 Capsule For Cerebral Cavernous Malformations
The Phase 1 study for OV888/GV101 capsule met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse eventsSecondary endpoint results indicate that the target pharmacokinetic profile was achieved at the targeted clinical dose, supporting once daily dosingOV888/GV101 capsule was shown to be biologically active in participants and elicited dose-dependent pharmacodynamic effects within the planned therapeutic dose rangeA Phase 2 study for the treatment of cerebral cavernous malformations is expected to initiate in the second half of 2024
7/1/24 8:03:48 AM ET
$OVID
Biotechnology: Pharmaceutical Preparations
Health Care

Ovid Therapeutics And Graviton Bioscience Announces Topline Data From Phase 1 Clinical Trial Studying OV888/GV101 Capsule For Cerebral Cavernous Malformations

Chat with this insight

Recent Analyst Ratings for $OVID

$OVID Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by President and COO Alexander Margaret A.

New insider Alexander Margaret A. claimed ownership of 28,125 shares (SEC Form 3)

SEC Form 4 filed by CBFO Rona Jeffrey A

$OVID Press Releases

Fastest customizable press release news feed in the world

Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results

Ovid Therapeutics to Host Investor Event

Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin

$OVID Leadership Updates

Live Leadership Updates

Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer

Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer

$OVID Financials

Live finance-specific insights

Ligand Reports Second Quarter 2024 Financial Results

$OVID Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Ovid Therapeutics downgraded by Oppenheimer

B. Riley Securities initiated coverage on Ovid Therapeutics with a new price target

H.C. Wainwright initiated coverage on Ovid Therapeutics with a new price target

$OVID Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Levin Jeremy M bought $50,364 worth of shares (18,248 units at $2.76), increasing direct ownership by 0.51% to 3,616,715 units (SEC Form 4)

$OVID Market Insights

Live Market Insights

Ovid Therapeutics Announces eNeuro Publishes Findings On The Anti-Convulsant Properties Of OV329 And Its Potential Effectiveness In Treatment-Resistant Seizures

HC Wainwright & Co. Reiterates Buy on Ovid Therapeutics, Maintains $3 Price Target

Ovid Therapeutics And Graviton Bioscience Announces Topline Data From Phase 1 Clinical Trial Studying OV888/GV101 Capsule For Cerebral Cavernous Malformations

$OVID Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Ovid Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Ovid Therapeutics Inc.

SEC Form SC 13G/A filed by Ovid Therapeutics Inc. (Amendment)

$OVID SEC Filings

SEC Form 10-Q filed by Ovid Therapeutics Inc.

Ovid Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 8-K filed by Ovid Therapeutics Inc.

Recent Analyst Ratings for
$OVID

$OVID
Insider Trading

$OVID
Press Releases

$OVID
Leadership Updates

$OVID
Financials

$OVID
Analyst Ratings

$OVID
Insider Purchases

$OVID
Market Insights

$OVID
Large Ownership Changes

$OVID
SEC Filings